#4ward trial

1 story

#debt facility #mavorixafor #neutropenia #whim syndrome #x4 pharmaceuticals #xfor #xolremdi

X4 Pharmaceuticals Extends Commercial Runway
X4 Pharmaceuticals secures $150m debt facility to extend commercial runway for XOLREMDI and mavorixafor.
Alphastreet - Earnings Decoded. Market Intelligence Delivered · 1m